首页> 外文期刊>Archives of disease in childhood >Aminoglycoside-induced deafness during treatment of acute leukaemia
【24h】

Aminoglycoside-induced deafness during treatment of acute leukaemia

机译:氨基糖苷引起的急性白血病耳聋

获取原文
获取原文并翻译 | 示例
       

摘要

Three unrelated children from ethnically diverse backgrounds who were treated for acute leukaemia became profoundly and irreversibly deaf during treatment. Aminoglycoside levels were within the therapeutic range. Genetic testing showed all three to have a maternally inherited mutation of mitochondrial DNA, m.1555A>G, known to cause sensitivity to the ototoxic effects of aminoglycosides. One child has received a cochlear implant, and another will be implanted shortly. Children diagnosed with acute leukaemia should be tested for this mutation at diagnosis, and alternative antibiotics chosen for the treatment of sepsis. Consideration should be given to elective testing of other groups of patients likely to receive aminoglycosides.
机译:在治疗期间,三名来自不同种族背景的无关儿童接受了急性白血病的治疗后,他们的听力严重且不可逆转地失聪。氨基糖苷水平在治疗范围内。基因测试表明,这三个基因均具有线粒体DNA的母体遗传突变,即m.1555A> G,已知该突变对氨基糖苷的耳毒性作用敏感。一个孩子已经接受了人工耳蜗植入,另一个将很快被植入。诊断为急性白血病的儿童应在诊断时测试此突变,并选择其他抗生素治疗败血症。应考虑对其他可能接受氨基糖苷类药物的患者进行选择性测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号